ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis

Zhang, Wenhui; Wang, Tao; Wang, Yan; Zhu, Feng; Shi, Haoqing; Zhang, Jili; Wang, Ziwei; Qu, Min; Zhang, Huaru; Wang, Tianyi; Qian, Yuping; Yang, Jinjian*; Gao, Xu*; Li, Jing*南方医科大学; 郑州大学; 同济大学; 1
Translational Oncology2022-2DOI: 10.1016/j.tranon.2021.101311
5被引8阅读
引用收藏
分享

摘要

Intratumor heterogeneity is a key driver for local relapse and treatment failure. Thus, using multifocal prostate cancer as a model to investigate tumor inter-clonal relationships and tumor evolution could aid in our understanding of drug resistance. Previous studies discovered genomic alterations by comparing hormone-sensitive prostate cancer (HSPC) with castration-resistant prostate cancer (CRPC) in large cohorts. However, most studies did not sequentially sample tumors from the same patient. In our study, we performed whole-exome sequencing (WES) on 14 specimens from five locally relapsed patients before and after androgen-deprivation therapy. We described the landscape of genomic alterations before and after treatment and identified critical driver events that could have contributed to the evolution of CRPC. In addition to confirming known cancer genes such as TP53 and CDK12, we also identified new candidate genes that may play a role in the progression of prostate cancer, including MYO15A, CHD6 and LZTR1. At copy number alteration (CNA) level, gain of 8q24.13-8q24.3 was observed in 60% of patients and was the most commonly altered locus in both HSPC and CRPC tumors. Finally, utilizing phylogenetic reconstruction, we explored the clonal progression pattern from HSPC to CRPC in each patient. Our findings highlight the complex and heterogeneous mechanisms underlying the development of drug resistance, and underscore the potential value of monitoring tumor clonal architectures during disease progression in a clinical setting.

学科与关键词

关键词
Clonal evolutionCRPCDrug resistanceIntratumor heterogeneityPrecision medicine
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Translational Oncology
发表日期
2022-02
卷期
第 16 卷
页码
101311
DOI
10.1016/j.tranon.2021.101311
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82022055]; Shanghai Rising-Star Program [20QA1411800]; Shanghai Hundred Talents Program [2018BR18]

作者

  • Z

    Zhang, Wenhui (第一作者)

    second mil med univ

  • W

    Wang, Tao

    1 · zhengzhou univ

查看全部 14 位作者收起作者
  • W

    Wang, Yan

    second mil med univ

  • Z

    Zhu, Feng

    tongji univ

  • S

    Shi, Haoqing

    second mil med univ

  • Z

    Zhang, Jili

    second mil med univ

  • W

    Wang, Ziwei

    second mil med univ

  • Q

    Qu, Min

    second mil med univ

  • Z

    Zhang, Huaru

    2 · southern med univ

  • W

    Wang, Tianyi

    second mil med univ

  • Q

    Qian, Yuping

    second mil med univ

  • Y

    Yang, Jinjian (通讯)

    1 · zhengzhou univ

  • G

    Gao, Xu (通讯)

    second mil med univ

  • L

    Li, Jing (通讯)

    second mil med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417